Multiple mechanisms underlie HLA dysregulation in cervical cancer

被引:96
作者
Brady, CS
Bartholomew, JS
Burt, DJ
Duggan-Keen, MF
Glenville, S
Telford, N
Little, AM
Davidson, JA
Jimenez, P
Ruiz-Cabello, F
Garrido, F
Stern, PL
机构
[1] Christie Hosp NHS Trust, Paterson Inst Canc Res, CRC, Immunol Grp, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Trust, Dept Cytogenet, Manchester M20 4BX, Lancs, England
[3] Royal Free Hosp, Anthony Nolan Res Inst, London NW3 2QG, England
[4] Manchester Royal Infirm, Transplantat Lab, Manchester M13 9WL, Lancs, England
[5] Univ Granada, Hosp Univ Virgen Nieves, Serv Anal Clin, Granada, Spain
来源
TISSUE ANTIGENS | 2000年 / 55卷 / 05期
关键词
cervical cancer; HPV vaccines; human papillomavirus; HLA; mutation; tumour immunotherapy;
D O I
10.1034/j.1399-0039.2000.550502.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The consistent dysregulation of HLA expression in cervical neoplasia is likely to influence the natural history of the disease and prospects for cell-mediated vaccine therapies. We have studied the underlying mechanisms in eight new cervical cancer cell lines derived from primary tumour biopsies. At least five independent mechanisms leading to changes in HLA expression were seen: HLA class I allelic transcription but no protein; abnormal HLA class I allelic transcription; no HLA-B locus transcription; loss of heterozygosity (LOH); no gamma IFN-mediated upregulation of HLA class I expression, and/or no interferon-gamma (gamma IFN)-mediated HLA class II induction. These were evident in different combinations in 7/8 cell lines showing that multiple, mostly irreversible mechanisms not overridden by gamma IFN, are responsible for HLA dysregulation in cervical neoplasia. Point mutations were responsible for lack of HLA-A2 expression in two cases. In cell line 808, the mutation encodes a stop codon in exon 3; in cell line 778, mutation of the first intron acceptor site leads to use of an alternative AG site in exon 2, resulting in a frameshift and a stop codon after the translation of only 38 amino acids. Tumour cells showing specific HLA class I loss may have selective advantage in the face of tumour-specific cytotoxic T cells (CTL). Such immune escape mechanisms present a major obstacle for the success of CTL-mediated therapies in cervical cancer.
引用
收藏
页码:401 / 411
页数:11
相关论文
共 36 条
  • [11] Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
    Garrido, F
    RuizCabello, F
    Cabrera, T
    PerezVillar, JJ
    LopezBotet, M
    DugganKeen, M
    Stern, PL
    [J]. IMMUNOLOGY TODAY, 1997, 18 (02): : 89 - 95
  • [12] Garrido F, 1997, GENETIC DIVERSITY HL, VII, P445
  • [13] GLEW SS, 1992, CANCER RES, V52, P4009
  • [14] Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: The ISRE-mediated route and a novel pathway involving CIITA
    Gobin, SJP
    Peijnenburg, A
    Keijsers, V
    vandenElsen, PJ
    [J]. IMMUNITY, 1997, 6 (05) : 601 - 611
  • [15] ANALYSIS OF CYTOMORPHOLOGICALLY ABNORMAL CERVICAL SCRAPES FOR THE PRESENCE OF 27 MUCOSOTROPIC HUMAN PAPILLOMAVIRUS GENOTYPES, USING POLYMERASE CHAIN-REACTION
    HUSMAN, AMD
    WALBOOMERS, JMM
    MEIJER, CJLM
    RISSE, EKJ
    SCHIPPER, MEI
    HELMERHORST, TM
    BLEKER, OP
    DELIUS, H
    VANDENBRULE, AJC
    SNIJDERS, PJF
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1994, 56 (06) : 802 - 806
  • [16] FREQUENCY OF DOWN-REGULATION OF INDIVIDUAL HLA-A AND HLA-B ALLELES IN CERVICAL CARCINOMAS IN RELATION TO TAP-1 EXPRESSION
    KEATING, PJ
    CROMME, FV
    DUGGANKEEN, M
    SNIJDERS, PJF
    WALBOOMERS, JMM
    HUNTER, RD
    DYER, PA
    STERN, PL
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 405 - 411
  • [17] Kisseljov F, 1996, INT J CANCER, V69, P484, DOI 10.1002/(SICI)1097-0215(19961220)69:6<484::AID-IJC12>3.0.CO
  • [18] 2-1
  • [19] KOLLER BH, 1985, J IMMUNOL, V134, P2727
  • [20] HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines
    Koopman, LA
    Mulder, A
    Corver, WE
    Anholts, JDH
    Giphart, MJ
    Claas, FHJ
    Fleuren, GJ
    [J]. TISSUE ANTIGENS, 1998, 51 (06): : 623 - 636